Browsing COVID-19 Research by Subject "IL-6 antagonists"
Now showing items 1-1 of 1
-
Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
( Lippincott Williams and Wilkins , 2022 , Article)Introduction: Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result ...